Davis TME, et al. - Whether therapeutic intensification in type 2 diabetes influences health status and quality of life (QoL) was determined in this investigation. Between 2008 and 2015, nine hundred thirty members in the longitudinal observational Fremantle Diabetes Study Phase II (mean age 65.3 years, 53.8% males, median diabetes duration 8.0 years) with valid data from baseline assessment and two biennial reviews (4 years of follow-up) were analyzed. Findings revealed that in community-based type 2 diabetes, treatment intensification including insulin initiation did not impact adversely on patient well-being. Outcomes suggested that worse glycaemic control and a greater risk of chronic complications, the burden of disease rather than treatment modality appears the primary determinant of health status and QoL since insulin use at entry was linked with longer diabetes duration.